Medicine, Cardiology Division

Grants

Grants per year 1999 2014 2015 2016 2017 2018 2019 2020 2021 2031

• 201 Active
• 602 Finished

Grants per year

Search results

• Active

  Mechanistic insights into the role of Zfp36 in cardiac lipid metabolism and cardiac response to pressure overload

  Ardehali, H.

  American Heart Association

  4/1/21 → 3/31/23

  Project: Research project

  • Lipid Metabolism 100%
  • Receptors, Tumor Necrosis Factor, Type I 73%
  • Pressure 59%
  • Peroxisome Proliferator-Activated Receptors 31%
  • Inflammation 30%

• Racial/Ethnic Disparities in Heart Failure: A cross-cohort collaboration

  Allen, N. B. & Ahmad, F.

  Kent County Memorial Hospital, National Heart, Lung, and Blood Institute

  4/1/21 → 3/31/25

  Project: Research project

  • Heart Failure 100%
  • Health 35%
  • Epidemiologic Studies 24%
  • Life Style 23%
  • Structural Models 16%

• Integrating a culturally competent APOL1 genetic testing program into living donor evaluation

  Gordon, E., Agrawal, A. H., Bonner, L. B., Duquette, D., Gargiulo, R. T., Shetty, A. A., Smith, J. D., Tandon, D. & Wicklund, C. A.

  National Institute of Diabetes and Digestive and Kidney Diseases

  4/1/21 → 3/31/26

  Project: Research project

  • Apolipoprotein L1 100%
  • Living Donors 50%
  • Genetic Testing 31%
  • African Americans 24%
  • Counseling 22%

• AHA Fellowship for Adovich Rivera in Support of Role of Social Determinants in Disease Control and Cardiometabolic Risk of People with Human Immunodeficiency Virus

  Feinstein, M. J.

  American Heart Association

  4/1/21 → 3/31/23

  Project: Research project

  • HIV 100%
  • Retention in Care 15%
  • Demography 13%
  • Metabolic Diseases 11%
  • Vulnerable Populations 11%

• Precision MRI of Left Atrial Fibrosis for Patients with Atrial Fibrillation

  Kim, D., Elbaz, M., Katsaggelos, A. K., Passman, R. S. & Ragin, A.

  National Heart, Lung, and Blood Institute

  3/10/21 → 2/28/25

  Project: Research project

  • Fibrosis 100%
  • Atrial Fibrillation 82%
  • Gadolinium 46%
  • Magnetic Resonance Spectroscopy 27%
  • Pulmonary Veins 24%

• Immunologic, Inflammatory, and Clinical contributors to HIV-Related Heart Failure with Preserved Ejection Fraction (HFpEF)

  Feinstein, M. J., Lloyd-Jones, D. M., Lomasney, J. W., Petito, L. C., Shah, S. J. & Thorp, E. B.

  National Heart, Lung, and Blood Institute

  2/25/21 → 1/31/25

  Project: Research project

  • Heart Failure 100%
  • HIV 96%
  • CD4-CD8 Ratio 8%
  • Cardiologists 7%
  • Patient Reported Outcome Measures 7%

• Prot#MYK-461-019: An Exploratory, Open-Label, Proof-of-Concept, Phase 2A Study OF Mavacamten (MYK-461) in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF) and Chronic Elevation of Cardiac Troponin I and/or NT-PROBNP

  Patel, R. B.

  Medpace Clinical Research LLC, MyoKardia, Inc.

  2/23/21 → 2/23/24

  Project: Research project

• Prot#D1690C00078: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Ha

  Tibrewala, A.

  TIMI Study Group, AstraZeneca Pharmaceuticals LP

  2/18/21 → 2/18/24

  Project: Research project

• Protocol# 09868: Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having Heart Failure with Preserved Ejection Fraction: Feasibility Study

  Patel, R. B.

  Axon Therapies, Inc

  2/12/21 → 2/11/24

  Project: Research project

• Prot#ABT-CIP-10310: Clinical Trial of Atrial Fibrillation Patients comparing Left Atrial Appendage Occlusion Therapy to Non-Vitamin K Antagonist Oral Anticoagulants

  Knight, B. P.

  St. Jude Medical Business Services, Inc.

  2/3/21 → 2/2/25

  Project: Research project

• Prot#09868: REBALANCE-HF STUDY CORE LAB - Northwestern University Echo Core Lab (NUECL) for project titled: Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having Heart Failure with Preserved Ejection Fraction: Randomized Controlle

  Freed, B. H.

  Axon Therapies, Inc

  1/25/21 → 1/30/23

  Project: Research project

• Prot#ABT-CIP-10349: Abbott Vascular Medical Device Registry (AV-MDR)

  Flaherty, J. D.

  Abbott Vascular Inc.

  1/21/21 → 1/20/25

  Project: Research project

• Circulating Endothelial Cells as Biomarkers of Cardiovascular Events in Patients with COVID-19

  Akhter, N. & Cristofanilli, M.

  Menarini Silicon Biosystems, Inc.

  1/7/21 → 1/7/24

  Project: Research project

• 4D Hemodynamic Signatures of Atrial Fibrillation, Ablation Efficacy & Risk of Stroke

  Elbaz, M., Greenland, P., Markl, M. & Passman, R. S.

  American Heart Association

  1/1/21 → 12/31/23

  Project: Research project

• The identification and pathophysiology of non-infarcted but injured myocardium in the post-ischemic heart

  Arora, R. K., Zhao, M., Arora, R. K., Jin, J., Kume, T., Kwasny, M. J. & Lomasney, J. W.

  National Heart, Lung, and Blood Institute

  1/1/21 → 12/31/24

  Project: Research project

  • myocardium 100%
  • infarction 99%
  • arrhythmia 95%
  • image analysis 93%
  • pathophysiology 91%

• Chicago Clinical Trials Unit

  Taiwo, B. O., Achenbach, C. J., Cohn, S. E., Feinstein, M. J., Galvin, S. R., Green, R., Hawkins, C. A., Maiga, M., Murphy, R. L., Palella Jr, F. J. & Cohn, S. E.

  National Institute of Allergy and Infectious Diseases

  12/1/20 → 11/30/27

  Project: Research project

  • HIV 100%
  • Clinical Trials 85%
  • National Institute of Allergy and Infectious Diseases (U.S.) 69%
  • Acquired Immunodeficiency Syndrome 52%
  • Comorbidity 14%

• Prot# 18940: The Role of Oxidative Injury in Creating a Vulnerable Substrate for Atrial Fibrillation in the Intact Atrium

  Passman, R. S. & Arora, R. K.

  St. Jude Medical, Cardiology Division, Inc.

  11/12/20 → 11/11/24

  Project: Research project

• Protocol #CS-200: iCLAS for Persistent Atrial Fibrillation

  Knight, B. P.

  Adagio Medical, Inc.

  11/6/20 → 11/6/23

  Project: Research project

• Prot#2020-05: Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device

  Davidson, C. J.

  Edwards Lifesciences LLC

  10/8/20 → 10/8/23

  Project: Research project

• Understanding the impact of stress reactivity on racial/ethnic disparities in cognitive function.

  Kershaw, K. N., Alexandria, S. J., Passman, R. S. & Sorond, F. A.

  National Institute on Aging

  9/1/20 → 8/31/22

  Project: Research project

  • Dementia 100%
  • Cognition 86%
  • Alzheimer Disease 77%
  • Ecological Momentary Assessment 55%
  • Alzheimer disease type 2 30%

• Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy

  Feinstein, M. J., Petito, L. C. & Thorp, E. B.

  National Heart, Lung, and Blood Institute

  8/1/20 → 6/30/24

  Project: Research project

  • Simian Immunodeficiency Virus 100%
  • HIV 82%
  • Heart Failure 70%
  • Immunotherapy 58%
  • Ischemia 56%

• Young Adult and Midlife Transitions in Physical Activity and Sedentary Behavior with Heart Failure Risk and Progression: Coronary Artery Risk Development in Young Adults (CARDIA)

  Carnethon, M. R. & Khan, S. S.

  University of Alabama at Birmingham, National Heart, Lung, and Blood Institute

  8/1/20 → 7/31/24

  Project: Research project

  • Heart Failure 100%
  • Sedentary Behavior 81%
  • Young Adult 78%
  • Coronary Vessels 73%
  • Exercise 70%

• Northwestern Genomic Risk Assessment and Management Program

  Chisholm, R. L., McNally, E. M., Rasmussen-Torvik, L. J., Gordon, A. S., Kho, A. N., Luo, Y., Perera, M., Roy-Puckelwartz, M. J., Scherr, C. E. L., Scholtens, D. M., Smith, M. E., Starren, J. B., Walunas, T. L., Wehbe, F., Aufox, S. A. & Hoell, C.

  National Human Genome Research Institute

  7/1/20 → 4/30/25

  Project: Research project

• The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)

  Ahmad, F.

  Duke University

  6/29/20 → 6/29/23

  Project: Research project

  • adverse events 100%
  • cardiovascular disease 93%
  • morbidity 75%
  • medicine 53%
  • infrastructure 52%

• Prot# ION-682884-CS2: A Phase 3 Global, Double-Blind, Randomized, Placebo‑Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin‑Mediated Amyloid Cardiomyopathy (ATTR CM)

  Shah, S. J.

  Pharmaceutical Research Associates, Inc., Ionis Pharmaceuticals, Inc.

  6/26/20 → 6/26/23

  Project: Research project